Current Issue 1 June 2012, Vol. 83, No. 2

Submit your best research to the Red Journal and receive a decision in about a month

The editorial team at the Red Journal is committed to providing authors a thorough review of their work in a quick timeframe. We return initial decisions less than 1 month after receiving a submission, on average. If accepted, articles are posted online in fully citable form within about 2 months after they are final. With an impact factor of 4.503, the Red Journal continues to work to bring timely and cutting-edge studies to our readers as quickly as possible. Click here to submit your best work for consideration.

CME Article

Issue Highlights

  • Oncology Scan – Head and Neck Cancers

    A regular feature where senior members of the Red Journal editorial team highlight recent articles related to the scientific literature that they feel are "must reads" for the radiation oncology community. Major articles are summarized and editorial comments are provided. This issue, Senior Editor Robert L. Foote, MD, FASTRO, reviews the best head-and-neck literature. He also explains recent changes to the head-and-neck cancers editorial section.

  • Role of Postmastectomy Radiation After Neoadjuvant Chemotherapy in Stage II-III Breast Cancer

    This critical review took as its objective the identification of a cohort of women treated with neoadjuvant chemotherapy and mastectomy for whom postmastectomy radiation may be safely omitted based on a low risk of local-regional failure (LRF). The authors used published data, hypothetical clinical scenarios, and an appropriateness criteria methodology to find such a cohort that will form the basis for prospective study.

  • Quality of Life After Hypofractionated Concomitant Intensity-Modulated Radiotherapy Boost for High-Risk Prostate Cancer

    This prospective study reports on patients undergoing elective pelvic nodal irradiation with a hypofractionated concomitant boost to the prostate (67.5Gy at 2.7Gy per fraction) together with androgen deprivation. There were only modest declines in urinary and bowel quality of life at 24 months following this regimen. Although more time will be required, this study bolsters the growing sense that creatively designed hypofractionated treatments are a tolerable and patient-friendly approach in the management of this disease.

  • Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group D9602 Study

    This important analysis from the Children's Oncology Group D9602 study supports the use of reduced radiation therapy doses for local control of rhabdomyosarcoma (RMS) in lymph node-negative, low-risk patients with either orbital primary tumors or microscopic tumor after resection. Cyclophosphamide- containing regimens are associated with lower rates of local failure for these patients. The current COG RMS protocols continue the use of these reduced RT doses, with the addition of a moderate cumulative dose of cyclophosphamide.

  • Risk of Radiation Retinopathy in Patients With Orbital and Ocular Lymphoma
    16 May 2012

    Megha Kaushik, Jose S. Pulido, Steven E. Schild, Scott Stafford

  • No Effect of the Transforming Growth Factor β1 Promoter Polymorphism C-509T on TGFB1 Gene Expression, Protein Secretion, or Cellular Radiosensitivity
    16 May 2012

    Sebastian Reuther, Elisabeth Metzke, Michael Bonin, Cordula Petersen, Ekkehard Dikomey, Annette Raabe

  • Dose Escalation of Total Marrow Irradiation With Concurrent Chemotherapy in Patients With Advanced Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
    16 May 2012

    Jeffrey Y.C. Wong, Stephen Forman, George Somlo, Joseph Rosenthal, An Liu, Timothy Schultheiss, Eric Radany, Joycelynne Palmer, Anthony Stein

  • Predictors of Toxicity After Image-guided High-dose-rate Interstitial Brachytherapy for Gynecologic Cancer
    16 May 2012

    Larissa J. Lee, Akila N. Viswanathan

  • Identification and Characterization of a Small Inhibitory Peptide That Can Target DNA-PKcs Autophosphorylation and Increase Tumor Radiosensitivity
    16 May 2012

    Xiaonan Sun, Chunying Yang, Hai Liu, Qi Wang, Shi-Xiu Wu, Xia Li, Tian Xie, Kathryn L. Brinkman, Bin S. Teh, E. Brian Butler, Bo Xu, Shu Zheng

  • View More Articles in Press...

On the Cover

Cover

See our companion journal, Practical Radiation Oncology also published by Elsevier.

Click here to see the scope of the two ASTRO journals.

Journal Ranking

Impact Factor: 4.503

Ranking 10th out of 111
Radiology category

Ranking 39th out of 184
Oncology category

© 2010 Journal Citation Reports®, Thomson Reuters

About The Red Journal

International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, offers authoritative articles linking new research and technologies to clinical applications. Original contributions by leading scientists and researchers include but are not limited to experimental studies of combined modality treatment, tumor sensitization and normal tissue protection, molecular radiation biology, particle irradiation, brachytherapy, treatment planning, tumor biology, and clinical investigations of cancer treatment that include radiation therapy. Technical advances related to dosimetry and conformal radiation treatment planning are also included.

Access this journal onSciVerse ScienceDirect
Print or Share This Page

Journal Access

We are pleased to offer all issues of the Red Journal online back to Volume 1, Issue 1. Access to abstracts is complimentary. Full articles are available to ASTRO members and print subscribers, and can be purchased or rented by nonsubscribers.

ASTRO Members: Log in here

Other Subscribers: Activate Online Access

Patients: Click here for low-cost access to articles.

Click here to join ASTRO and receive the Journal as a member benefit.

Submission Fees

Starting October 1, the Red Journal will begin requiring a $75 fee for all clinical submissions. The recent incredible rise in the number of journal submissions has led to a significant increase in the expenses related to the peer review process. These fees will help offset a portion of these costs. Thank you for your support of the Journal.

ASTRO Information

ASTRO

The mission of ASTRO is to advance the practice of radiation oncology by disseminating the results of scientific research, promoting excellence in patient care, providing opportunities for educational and professional development of its members and representing radiation oncology in a rapidly evolving socioeconomic healthcare environment. Members of ASTRO will strive for excellence in clinical, research and educational domains in the use of radiation therapy and will be partners in the multidisciplinary quest to eradicate cancer as a cause of death and suffering.

Visit the new RT Answers

ASTRO

ASTRO's patient resource at www.rtanswers.org has a new look. Based on feedback from patients and health care professionals, the site has been redesigned to be more user-friendly. It includes more pictures of treatments and includes an advanced "Doctor Finder" feature to allow patients to search for a radiation oncologist based on location, diseases treated, and languages spoken. New for the site is a "Be an Advocate" section that helps people with cancer and their families get involved in advocacy in the cancer community. Visit www.astro.org/MyASTRO/Products/index.aspx to order RT Answers posters to hang in your clinic.